| Alvocidib | |
|---|---|
|
2-(2-chlorophenyl)-5,7-dihydroxy-8-[(3S,4R)-3-hydroxy-1-methyl-4-piperidinyl]-4-chromenone |
|
| Identifiers | |
| CAS number | 146426-40-6 |
| PubChem | 5287969 |
| ChemSpider | 4450222 |
| DrugBank | DB03496 |
| MeSH | Flavopiridol |
| ChEMBL | CHEMBL428690 |
| Jmol-3D images | Image 1 |
|
|
|
|
| Properties | |
| Molecular formula | C21H20ClNO5 |
| Molar mass | 401.8402 |
| Except where noted otherwise, data are given for materials in their standard state (at 25 °C, 100 kPa) |
|
| Infobox references | |
Alvocidib (INN; also known as Flavopiridol or HMR-1275) is a cyclin-dependent kinase inhibitor under clinical development for the treatment of chronic lymphocytic leukemia. It has been studied also for the treatment of arthritis[1] and atherosclerotic plaque formation [2] The target of Flavopiridol is the positive transcription elongation factor P-TEFb.[3][4] Treatment of cells with Flavopiridol leads to inhibition of P-TEFb and the loss of mRNA production.[5][6]
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| This antineoplastic or immunomodulatory drug article is a stub. You can help Wikipedia by expanding it. |
This entry is from Wikipedia, the leading user-contributed encyclopedia. It may not have been reviewed by professional editors (see full disclaimer)